Emerging Markets Regulatory Tracker: China Approves Sabin Vaccine
This article was originally published in PharmAsia News
Executive Summary
China has approved a domestically developed Sabin vaccine for polio.
For the previous article in the series, see: (Also see "Emerging Markets Regulatory Tracker: India (Vol. 5 No. 2)" - Scrip, 7 Jan, 2015.).
China approves world’s first Sabin inactivated polio vaccine
The China FDA has announced
the marketing approval of the world’s first Sabin strain inactivated polio vaccine that was independently developed by China’s Institute of Medical Biology, at the Academy of Medical Sciences.
The agency acknowledges the assistance through seminars of the World Health Organization (WHO), the US Centers for Disease Control (CDC), Japan’s National Institute of Infectious Diseases (NIID), the European Medicines Agency (EMA), and the UK, in the review of the vaccine.
China intends to provide the vaccine to developing countries through the WHO’s polio eradication program.
Read all Breaking News from RegLink.
